Fig. 5

IL-13 induces miR-137 upregulation and HCRT downregulation in vitro and in vivo. (A) Stimulation of human neuroblastoma cells (SK-N-DZ) with IL-13 at concentrations of 0.005 ng/µL (n = 9), 0.01 ng/µL (n = 15), and 0.05 ng/µL (n = 12). RNA was isolated and miR-137 and HCRT expression analyzed by qRT-PCR. Data are from seven independent cell culture experiments and presented as the mean fold change difference compared with vehicle ± SEM (one-way ANOVA with Dunnett’s post hoc test comparing to vehicle group; *P < 0.05; **P < 0.01). (B) Schematic overview of IL-13 injection (0.01 µg/µL, intraperitoneal) and timing of termination. (C) Expression analysis of mmu-miR-137 (ZT18 control vs. IL-13 injection; n = 10 and 11, respectively) and mmu-miR-665 (ZT18 control vs. IL-13 injection; n = 9 and 11, respectively). Data are presented as the magnitude of difference compared with vehicle ± SEM (two-way ANOVA with Sidak post hoc comparisons of treatment group to control group at each time point; *P < 0.05). (D) HCRT mRNA determined by qRT-PCR and HCRT-1 peptide levels determined by RIA. ZT18 control vs. IL-13 injection; n = 10 and n = 11, respectively. Data are presented as mean ± SEM (two-way ANOVA with Sidak post hoc comparisons of treatment group to control group at each time point; *P < 0.05).